JTCS St. Jude Medical
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Ludwig C. Mueller
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dunst, K. M.
Right arrow Articles by Mueller, L. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dunst, K. M.
Right arrow Articles by Mueller, L. C.
Related Collections
Right arrow Lung - other

J Thorac Cardiovasc Surg 2004;128:621-622
© 2004 The American Association for Thoracic Surgery

Brief communication

Surgical management of bilateral multiple invasive pulmonary aspergillosis

Karin M. Dunst, MDa,*, Ludwig C. Mueller, MDa

a Department of Cardiac Surgery, Leopold-Franzens University Innsbruck, Austria

Received for publication January 6, 2004; revisions received January 31, 2004; accepted for publication February 4, 2004.

* Address for reprints: Karin M. Dunst, MD, Department of Cardiac Surgery, University Hospital Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria
Karin.dunst@uibk.ac.at

The first 20% of the full text of this article appears below.


Dr Dunst


There are 3 clinical types of pulmonary aspergillosis. The allergic and saprophytic forms can be encountered in immunocompetent patients, whereas invasive pulmonary aspergillosis (IPA) is a life-threatening opportunistic infectious complication that develops in the immunocompromised host as a consequence of impaired defense function.1 IPA represents a major source of morbidity and mortality in the neutropenic patient. The clinical symptoms are sometimes masked, especially in the setting of a malignant neoplastic disorder; however, as a rule, there is productive cough and hemoptysis up to life-threatening bleeding. Standard therapy consists of amphotericin B, itraconazole, or both2; however, new antifungal agents, such as voriconazole3 or caspofungin,4 . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2004 by The American Association for Thoracic Surgery.